An investigation concluded recently in order to determine the cost-effectiveness of treatment with caffeine compared with placebo for Sleep Apnea of prematurity in infants with birth weight less than 1250 g, from birth through corrected age 18 to 21 months.
The researchers took a retrospective economic evaluation of cost-per-survivor without someone neurodevelopmental impairment by using data-patient from caffeine for Sleep Apnea Prematurity clinical trial (N = 1869).
Researchers include direct medical expenses or claims payer or hospital but excluding costs for parents and society, such as loss of productivity. Our price $ 0.00/mg of caffeine citrate generic for our base-case analysis. All expenditure shall be expressed in dollars Canada 2008 and discounted at 3%. The time horizon for the analysis is extended through 18 and 21 months corrected age to match the clinical trial.
The average cost per infant was $ 124 466 in caffeine and $ 133 505 in the placebo group (difference: $ 9039 [–14 749 to – 375] corrected P =. 014).
Cost-effectiveness analysis showed that caffeine is a dominant position or "win-win" therapies: > 99% of 1000 bootstrap propagation analysis, caffeine-treated infants had lower average costs and simultaneously better results. These results were strong in 1000% increase in elements of individual resource, including the price of caffeine citrate.
Compared with placebo therapies caffeine for Sleep Apnea of prematurity in infants weighing less than 1250 g financially attractive for infants up to 18 and 21 months corrected age.
Tagged with:caffeine ‧ clinical trial ‧ direct cost medical ‧ Sleep Apnea babies ‧ insurance payer ‧ Sleep Apnea Kids ' ‧ ‧ Sleep Apnea Sleep Apnea in children
Filed under:clinical research sleep ‧ ‧ ‧ Sleep Apnea ‧ ‧ Sleep Apnea research Sleep Apnea treatment ‧ ‧ Sleep Apnea in children who sleep problems clinical trials
Like this post? subscribe to my RSS feed and get loads more!
沒有留言:
張貼留言